《大行報告》摩通:內地醫療股估值正觸底 看好醫藥合同外包服務(CXO)板塊等
摩通發表研究報告指出,從估值、營運業績及政策角度來看,現在是投資內地醫療股的時機。該行認為,內地醫療股估值正觸底,其估值目前接近過去五年的市盈率範圍底部,而中國機構基金於醫療股的倉位相對較低,約為其資產管理規模的11%,較過去五年的平均水平低。
此外,該行認為隨著第二季與疫情相關的封鎖措施解除後,患者到訪及手術量正逐步恢復,預期醫療企業將於今年下半年實現較好的業績。
該行建議目前可投資於內地醫療股,並強烈推薦醫療器械、醫療保健服務及醫藥合同外包服務(CXO)板塊。當中,認為醫療器械板塊最能受惠於政策,如邁瑞醫療(300760.SZ)(評級「增持」);醫療保健服務板塊將從疫情中逐漸復甦;至於CXO板塊增長持續強勁,受美國生物製藥經濟措施的影響有限。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.